• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Immediately Execute Tender Offer followed by Share Buyback

    1/15/25 8:05:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $INMD alert in real time by email

    Believes the Board Must Immediately Execute a Tender Offer for 30% of the Company

    Lays Out Action Plan to Restore Investor Confidence, Including an additional 10% Share Buyback in 2025

    Announces Intent to Fight for Shareholders Should InMode Not Take Appropriate Action

    MIAMI, Jan. 15, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd. (NYSE: INMD) ("InMode") today sent a letter to the Board of Directors of InMode (the "Board") urging the Board to accelerate and increase its stock repurchase. 

    (PRNewsfoto/DOMA Perpetual)

    The letter can be downloaded here

    The full text of the letter follows:

    January 15, 2025

    To the Board of Directors of InMode Ltd.:

    As you are aware from our previous communications, including our public letter of July 25, 2024i, we are among the largest shareholders of InMode Ltd. ("InMode" or the "Company").ii We are disappointed that the Company's stock price has not improved since our last public letteriii: in the wake of the Company's recent announcement of lower sales for Q4 of 2024, the stock price now sits at around $16 per share.iv1 At the same time, InMode is clearly full of cash. At the end of Q3 2024 it reported $684 million in cash on the books, and we estimate it currently still holds about $640 million.v The balance sheet has no debt and our analysis, based on the Company's extremely conservative 2025 guidance, indicates that the Company should produce about $150 million of free cash flow in 2025, if not morevi. In less than three years, the Company's entire market cap as it stands today will be cash.vii

    According to our analysis, InMode's current market capitalization is trading at less than the cash on hand plus projected 3-year cumulative free cash flow.viii This is the lowest valuation in the history of the Company and one of the lowest valuations we have ever seen for a company with InMode's margin profile and dominance in its niche.ix The Company's board of directors ("Board") has no excuse not to act while the Company's stock is so historically cheap. The substantial cash on the Company's balance sheet belongs to its shareholders and should be returned to them without delay.

    The Board should immediately execute a tender offer for 30% of the Company, to be followed by a 10% buyback for 2025.

    InMode has no debt and maintains significant free cash flow.x It is irresponsible and wholly inefficient to run a business with this margin profile while maintaining such an enormous amount of cash, hoarding shareholder money without making efforts to improve shareholder returns. The company must reduce its cash level to less than $100 million if it hopes to restore shareholder confidence in a Board that has apparently fallen asleep at the wheel.

    While the announcement of lower sales for Q4 of 2024 is disappointing, the larger issue at hand is the Board's failure of oversight.xi While the Board is failing shareholders on many levels, the three issues below indicate what we can only characterize as a clear-cut breach of its duties and responsibilities to the owners of the business.

    First, recent actions of management – in particular, those taken by CEO Moshe Mizrahy – continue to create instability in the Company that we believe is driving down the Company's stock price. Notably, Mr. Mizrahy fired key senior executives ahead of the most important quarter of the year, including the Head of Sales for North America, a region which represents more than 50% of the Company's revenues.xii Of course, making personnel updates and refreshing talent is the prerogative of the CEO, but this is not what Mr. Mizrahy has done. Instead, he has simply left this crucial position empty and apparently, arranging for the sales teams to report directly to him. No one should be surprised that sales are down under these circumstances. This strikes us as grossly irresponsible behavior for the CEO of a publicly-traded company, and yet the Board has allowed it to continue despite the obvious negative consequences.

    Second, the Board and management have made no concrete efforts to diversify production away from Israel.xiii We have encouraged this path on multiple occasions in our communications with the Company and have suggested the Dominican Republic or Costa Rica as possible locations. As we've expressed to the Board, this would lower costs and secure a portion of the supply chain outside of a country at war, and yet we've seen no movement to address these critical concerns. It is the responsibility of the Board to represent the true owners of the business, the Company's shareholders, and to provide appropriate oversight of that business, which necessarily includes awareness of and appropriate action taken with respect to key risks. Inaction in the face of these risks is, in our view, clearly a breach of those responsibilities.

    Finally, as we've expressed above, the significant amount of cash on the balance sheet belongs to shareholders and should be returned to them. In its latest earnings release, the Company reported $685 million in cash on the balance sheet at the end of Q3 2024.xiv Per our calculations, even if the Company completed its announced buyback, there should be about $640 million remaining on the balance sheet.xv Assuming 70 million shares after the completion of the buyback and a price of $16 per share, the market cap of the Company would now be $1.1 billion.xvi If the $150 million in free cash flow we estimate based on the Company's 2025 guidance is indicative of the future trend, in less than three years the Company's entire market cap would consist of cashxvii – an absurd outcome for a company like InMode that could only come about through gross balance sheet mismanagement and failure of Board oversight.

    To correct these issues, InMode should immediately:

    1. Name new Heads of Sales for all relevant regions and present them to the market. On a quarterly basis, the Company should disclose to investors improvements in sales by region. It is unacceptable to attempt to run a business without proper sales teams, and the announcement of new Heads of Sales and these ongoing disclosures are critical to restoring investor confidence.
    2. Address crucial business risks by moving a significant portion of production outside of Israel. This is critical for security and stability and will allow the Company to lower costs.
    3. Announce and execute a 30% tender offer of stock in Q1 2025, immediately followed by a 10% buyback for 2025. With massive piles of cash on the balance sheet and the Company's valuation at an all-time low, this is the best and most accretive way to allocate capital.xviii
    4. Open a small dividend of no more than $15 million in 2025 to start. Bringing the Company's yield to 1 to 2% a year, with small annual increases to follow, will bolster shareholder returns and create a path for shareholders who only invest in dividend-paying stocks to participate in the business.
    5. Bring cash levels down of the Company to less than $100 million and obtain a large revolving credit line in the event there is an urgent need for cash. Hoarding hundreds of millions of dollars in cash in case of an emergency, such as disruption of production caused by the war, is not the right way to address this risk and only harms shareholders. The Board has duties to its shareholders to appropriately steward their capital, and it is time to start acting like it.
    6. Strategically allocate capital until cash balances reach an efficient, effective level. Additional buybacks in Q1 2026 may be required, if many hundreds of millions of dollars remain on the balance sheet due to the business's strong free cash flow. If the valuation still remains low, the Company should execute another minimum 10% buyback in 2026.

    InMode possesses superior intellectual property, to which its high margins and enormous free cash flow are testament.xix The recent destabilizing actions by its CEO, the failure to address key business risks, and the mismanagement of the Company's balance sheet have all contributed to a significantly depressed valuation and loss of investor confidence. But the Board still has an opportunity to correct course by taking advantage of the current valuation to return the Company's tremendous pile of cash to the shareholders to whom it belongs.

    The Board has a legal and fiduciary responsibility to its shareholders. The path to honoring that responsibility is clear, and in the absence of corrective action by the Board, we intend to take whatever steps we believe necessary to hold the Board and management accountable to protect our rights. To that end, we have retained Olshan Frome Wolosky LLP as legal counsel in the United States and Barnea Jaffa Lande & Co. in Israel to advise us in the event we are forced to take action to fight for the Company's shareholders and its future.

    Regards,

    Pedro Escudero

    CEO & CIO

    DOMA Perpetual Capital Management LLC

    About DOMA Perpetual Capital Management LLC:

    DOMA Perpetual Capital Management LLC is an asset management firm based in Miami, Florida. DOMA Perpetual strives to achieve great investment results by identifying attractive, uncorrelated companies with sustainable competitive advantages, while limiting exposure to downside risks. It employs an opportunistic, fundamentals-based strategy that invests in companies across a variety of sectors and market caps throughout the globe.

    Contact:

    DOMA Perpetual Capital Management LLC

    [email protected]

    Disclaimer

    This letter has been prepared by DOMA Perpetual Management LLC and its affiliates ("DOMA").  The views expressed herein reflect the opinions of DOMA and are based on publicly available information with respect to InMode Ltd. ("InMode, Ltd." or the "Company"). DOMA recognizes that there may be confidential information in the possession of the Company that could lead it or others to disagree with DOMA's conclusions. DOMA reserves the right to change or modify any of such views or opinions at any time and for any reason and expressly disclaims any obligation to correct, update, or revise the information contained herein or to otherwise provide any additional materials.

    For the avoidance of doubt, this press release was not produced by any person that is affiliated with InMode Ltd., nor was its content endorsed by InMode Ltd. This press release is provided merely as information and is not intended to be, nor should it be construed as, an offer to sell or a solicitation of an offer to buy any security nor as a recommendation to purchase or sell any security. One or more funds managed by DOMA currently beneficially owns shares of the Company.

    Some of the materials in this press release contain forward-looking statements. All statements contained herein that are not clearly historical in nature or that necessarily depend on future events are forward-looking, and the words "anticipate," "believe," "expect," "potential," "could," "opportunity," "estimate," "plan," "once again," "achieve," and similar expressions are generally intended to identify forward-looking statements. The projected results and statements contained herein that are not historical facts are based on DOMA's current expectations, speak only as of the date of these materials and involve risks, uncertainties and other factors that may cause actual results, performances or achievements to be materially different from any future results, performances or achievements expressed or implied by such projected results and statements. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of DOMA.

    1 All references to $ are USD.

    i Doma Perpetual Capital Management LLC., (2024, July 25). Doma perpetual sends letter to the board of directors of InMode urging the execution of a 40% tender offer. PR Newswire. https://www.prnewswire.com/news-releases/doma-perpetual-sends-letter-to-the-board-of-directors-of-inmode-urging-the-execution-of-a-40-tender-offer-302206114.html

    ii Bloomberg Database, DOMA Perpetual Internal Calculations

    iii Bloomberg Database

    iv Bloomberg Database

    v InMode Company Filings, DOMA Perpetual Internal Calculations

    vi InMode Company Filings, DOMA Perpetual Internal Calculations

    vii DOMA Perpetual Internal Calculations

    viii DOMA Perpetual Internal Calculations

    ix Bloomberg Database, DOMA Perpetual Internal Calculations

    x InMode Company Filings, DOMA Perpetual Internal Calculations

    xi InMode Ltd., (2025, January 8). INMODE to report Fourth Quarter & full year 2024 financial results and hold conference call on February 6, 2025, expects Q4 revenue between $97.0m-$97.5m. PR Newswire. https://www.prnewswire.com/news-releases/inmode-to-report-fourth-quarter--full-year-2024-financial-results-and-hold-conference-call-on-february-6--2025---expects-q4-revenue-between-97-0m-97-5m-302345003.html

    xii InMode Ltd., (2024, October 1). INMODE announces departures of president of North America, chief medical officer and VP of sales USA as part of a global reorganization strategy. PR Newswire. https://www.prnewswire.com/news-releases/inmode-announces-departures-of-president-of-north-america-chief-medical-officer-and-vp-of-sales-usa-as-part-of-a-global-reorganization-strategy-302263201.html, InMode Company Filings, DOMA Perpetual Internal Calculations

    xiii InMode Earnings Calls and Conference Presentations

    xiv InMode Q3 2024 Earnings Release

    xv InMode Company Filings, DOMA Perpetual Internal Calculations

    xvi DOMA Perpetual Internal Calculations

    xvii DOMA Perpetual Internal Calculations

    xviii InMode Company Filings, DOMA Perpetual Internal Calculations

    xix InMode Company Filings, DOMA Perpetual Internal Calculations

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/doma-perpetual-sends-letter-urging-board-of-directors-of-inmode-ltd-to-immediately-execute-tender-offer-followed-by-share-buyback-302351152.html

    SOURCE DOMA Perpetual

    Get the next $INMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INMD

    DatePrice TargetRatingAnalyst
    4/29/2025Buy → Neutral
    BTIG Research
    4/28/2025$22.00 → $16.00Outperform → Neutral
    Robert W. Baird
    10/17/2024$25.00Buy
    BTIG Research
    7/23/2024$21.00 → $19.00Buy → Hold
    Jefferies
    11/3/2023$52.00 → $24.00Buy → Neutral
    UBS
    10/13/2023$55.00 → $22.00Buy → Hold
    Canaccord Genuity
    3/29/2023$40.00Buy
    UBS
    2/17/2023Buy → Hold
    Needham
    More analyst ratings

    $INMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by InMode Ltd.

    3 - InMode Ltd. (0001742692) (Issuer)

    3/18/26 7:09:10 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by InMode Ltd.

    3 - InMode Ltd. (0001742692) (Issuer)

    3/18/26 7:06:52 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Mizrahy Moshe

    3 - InMode Ltd. (0001742692) (Issuer)

    3/18/26 7:08:06 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    InMode downgraded by BTIG Research

    BTIG Research downgraded InMode from Buy to Neutral

    4/29/25 8:06:22 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded InMode from Outperform to Neutral and set a new price target of $16.00 from $22.00 previously

    4/28/25 1:56:11 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BTIG Research initiated coverage on InMode with a new price target

    BTIG Research initiated coverage of InMode with a rating of Buy and set a new price target of $25.00

    10/17/24 7:41:34 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    InMode to Present at the 25th Annual Needham Virtual Healthcare Conference

    YOKNEAM, Israel, March 24, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced that Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial Officer will present at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026. The fireside chat, moderated by Michael Matson, Senior Equity Analyst, is scheduled for 11:00 am Eastern Time on Monday, April 13, and a live webcast of the presentation can be accessed here. InMode will also hold virtual one-on-one investor meetings

    3/24/26 8:30:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode Announces New Share Repurchase Program

    YOKNEAM, Israel, March 13, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that its Board of Directors has authorized a new share repurchase program for up to approximately 10% of the Company's total shares outstanding, representing approximately 6.38 million ordinary shares. In 2025, the Company repurchased approximately $127.4 million of its outstanding ordinary shares through share repurchase programs. Despite a challenging macroeconomic environment, the Company continues to generate strong cash fl

    3/13/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode to Present at Upcoming Investor Conferences

    YOKNEAM, Israel, Feb. 26, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences in March: Barclays 28th Annual Global Healthcare ConferencePresenters: Yair Malca, Chief Financial Officer Format: In-person fireside chat moderated by Matt Miksic, Senior Equity Analyst, and one-on-one meetingsLocation: Miami, FLWhen: Wednesday, March 11 at 12:30 pm ETA live webcast of the presentation can be accessed here.Oppenheimer 36th Annual Healthcare MedTech & Services ConferencePresenters: Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial OfficerFormat: Virt

    2/26/26 8:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    SEC Filings

    View All

    SEC Form 6-K filed by InMode Ltd.

    6-K - InMode Ltd. (0001742692) (Filer)

    3/13/26 7:00:09 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 6-K filed by InMode Ltd.

    6-K - InMode Ltd. (0001742692) (Filer)

    2/23/26 7:00:19 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form S-8 filed by InMode Ltd.

    S-8 - InMode Ltd. (0001742692) (Filer)

    2/10/26 7:38:08 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Leadership Updates

    Live Leadership Updates

    View All

    InMode Appoints Michael Dennison as President of North America

    IRVINE, Calif., Nov. 3, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, has appointed Michael Dennison, most recently Vice President of Sales, as President of North America.  Dennison has held nearly every sales position in the aesthetic medical device industry, consistently producing at the highest level in each. With close to a decade of leadership experience at InMode, Dennison has advanced through roles from District Sales Manager to Vice President of Sales, driving national revenue growth, expanding market shar

    11/3/25 8:05:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Financials

    Live finance-specific insights

    View All

    InMode Reports Fourth Quarter and Full Year 2025 Financial Results: Quarterly GAAP Revenue of $103.9 Million and Full Year Revenue of $370.5 Million

    YOKNEAM, Israel, Feb. 10, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the fourth quarter and full year of 2025. Fourth Quarter 2025 Highlights: Quarterly GAAP revenues of $103.9 million, compared to $97.9 million in the fourth quarter of 2024.Quarterly revenues from consumables and service of $21.5 million, an increase of 8% compared to the fourth quarter of 2024.GAAP operation income of $26 million, *non-GAAP operation income of $28.5 million.Total cash position of $555.3 million as of December 31, 2025, including cash and cash equivalents, marketable securiti

    2/10/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode to Report Fourth Quarter & Full Year 2025 Financial Results and Hold Conference Call on February 10, 2026, Expects Q4 Revenue Between $103.6M-$103.8M

    Conference call to be held on Tuesday, February 10, 2026, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Jan. 8, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the fourth quarter and full year of 2025 before the Nasdaq market opens on Tuesday, February 10, 2026. InMode is currently finalizing its financial results for the fourth quarter and full year of 2025. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of InMode's financial results for such period, subject to final adjustments and ot

    1/8/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode Reports Third Quarter 2025 Financial Results: Quarterly Revenue of $93.2 Million, 78% Gross Margins

    YOKNEAM, Israel, Nov. 5, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights: Quarterly GAAP revenues of $93.2 million, compared to $130.2 million in the third quarter of 2024, which included $31.9 million of pre-order sales.Quarterly revenues from consumables and service of $19.9 million, an increase of 26% compared to the third quarter of 2024.GAAP operating income of $20.9 million. *Non-GAAP operating income was $23.6 million.Total cash position of $532.3 million as of September 30, 2025, incl

    11/5/25 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

    SC 13G/A - InMode Ltd. (0001742692) (Subject)

    2/13/24 4:31:18 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

    SC 13G/A - InMode Ltd. (0001742692) (Subject)

    2/13/24 4:25:40 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by InMode Ltd.

    SC 13G - InMode Ltd. (0001742692) (Subject)

    2/6/24 9:36:39 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care